Abstract: A system and method, in particular computer implemented method for determining a perturbation for attacking and/or validating an association tracker. The method includes providing digital image data that includes an object, determining with the digital image data a first feature that characterizes the object, providing in particular from a storage a second feature that characterizes a tracked object, determining the perturbation depending on a measure of a similarity between the first feature and the second feature.

Abstract: The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.

Abstract: The invention relates to a coated famotidine particle having at least a core and a coating layer, wherein the particle core comprises famotidine, a first filler and a first binder; and wherein the coating layer is substantially free from famotidine and comprises a second filler and a second binder. The invention also relates to solid dosage forms comprising said coated famotidine particle, and the use of the coated famotidine particle for treating a subject suffering from a disease or disorder in the gastrointestinal tract.

Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

Abstract: The present invention is directed to an orally disintegrable multi-layered particle comprising a hydrophobic core containing simethicone, a hydrophilic surfactant layer, and a hydrophilic disintegrant layer; wherein said hydrophilic surfactant layer is located between the hydrophobic core and the hydrophilic disintegrant layer; and orally disintegrable solid dosage forms comprising said multi-layered particle, and related processes.

Abstract: A system and method, in particular computer implemented method for determining a perturbation for attacking and/or validating an association tracker. The method includes providing digital image data that includes an object, determining with the digital image data a first feature that characterizes the object, providing in particular from a storage a second feature that characterizes a tracked object, determining the perturbation depending on a measure of a similarity between the first feature and the second feature.

Abstract: The invention relates to a gel-chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the gel-chewable dosage form and wherein the gel-chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the gel-chewable dosage form.

Abstract: The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.

Abstract: The present invention is directed to a method of reducing the risk of infection following surgery utilizing the drug eluting surgical screw disclosed herein to secure an implant in an animal following surgery. The drug eluting screw includes a drug eluting component that can elute a therapeutic agent locally at the surface of the implant reducing the risk of infection.

Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

Abstract: The present invention is directed to a method of reducing the risk of infection following surgery utilizing the drug eluting surgical screw disclosed herein to secure an implant in an animal following surgery. The drug eluting screw includes a drug eluting component that can elute a therapeutic agent locally at the surface of the implant reducing the risk of infection.

Abstract: The present invention provides a drug eluting surgical screw and a method for manufacturing a drug eluting surgical screw. The drug eluting surgical screw may include a shaft having a threaded portion, a head having a drive recess disposed at a proximal end of the shaft, the drive recess having a reservoir region and a driver engagement region, and at least one or more drug eluting components disposed within the reservoir region of the drive recess in a manner that does not substantially impair a connection between a driver and the surgical screw when the driver is operably disposed within the driver engagement region, each of the at least one or more drug eluting components including a carrier matrix and a therapeutic agent, the therapeutic agent being at least 20 wt % of the drug eluting component prior to any implantation of the drug eluting surgical screw.

Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

Abstract: The present invention is directed to a process for making a dosage form comprising at least one pharmaceutically active ingredient, the method comprising the steps of (i) providing a shape of the dosage form comprising at least two powder layers, wherein the first powder layer comprises a surface stabilizing agent and the second powder layer comprises at least one activator and the pharmaceutically active ingredient, wherein the activator has a Q value of less than 75; (ii) applying a radiofrequency energy for a sufficient period of time to the shape of step (i); and (iii) applying heat for a sufficient period of time to the shape of step (i).

Abstract: The present invention provides a drug eluting surgical screw and a method for manufacturing a drug eluting surgical screw. The drug eluting surgical screw may include a shaft having a threaded portion, a head having a drive recess disposed at a proximal end of the shaft, the drive recess having a reservoir region and a driver engagement region, and at least one or more drug eluting components disposed within the reservoir region of the drive recess in a manner that does not substantially impair a connection between a driver and the surgical screw when the driver is operably disposed within the driver engagement region, each of the at least one or more drug eluting components including a carrier matrix and a therapeutic agent, the therapeutic agent being at least 20 wt % of the drug eluting component prior to any implantation of the drug eluting surgical screw.

Abstract: The present invention provides a drug eluting surgical screw and a method for manufacturing a drug eluting surgical screw. The drug eluting surgical screw may include a shaft having a threaded portion, a head having a drive recess disposed at a proximal end of the shaft, the drive recess having a reservoir region and a driver engagement region, and at least one or more drug eluting components disposed within the reservoir region of the drive recess in a manner that does not substantially impair a connection between a driver and the surgical screw when the driver is operably disposed within the driver engagement region, each of the at least one or more drug eluting components including a carrier matrix and a therapeutic agent, the therapeutic agent being at least 20 wt % of the drug eluting component prior to any implantation of the drug eluting surgical screw.

Abstract: The present invention provides a drug eluting surgical screw and a method for manufacturing a drug eluting surgical screw. The drug eluting surgical screw may include a shaft having a threaded portion, a head having a drive recess disposed at a proximal end of the shaft, the drive recess having a reservoir region and a driver engagement region, and at least one or more drug eluting components disposed within the reservoir region of the drive recess in a manner that does not substantially impair a connection between a driver and the surgical screw when the driver is operably disposed within the driver engagement region, each of the at least one or more drug eluting components including a carrier matrix and a therapeutic agent, the therapeutic agent being at least 20 wt % of the drug eluting component prior to any implantation of the drug eluting surgical screw.

Abstract: The present invention provides a drug eluting surgical screw and a method for manufacturing a drug eluting surgical screw. The drug eluting surgical screw may include a shaft having a threaded portion, a head having a drive recess disposed at a proximal end of the shaft, the drive recess having a reservoir region and a driver engagement region, and at least one or more drug eluting components disposed within the reservoir region of the drive recess in a manner that does not substantially impair a connection between a driver and the surgical screw when the driver is operably disposed within the driver engagement region, each of the at least one or more drug eluting components including a carrier matrix and a therapeutic agent, the therapeutic agent being at least 20 wt % of the drug eluting component prior to any implantation of the drug eluting surgical screw.

Abstract: Improved techniques to create, browse, rate and/or purchase media asset groups are disclosed. Media assets groups can be created by various users and published to a digital assets manager. Thereafter, the media assets groups can be finalized and made available for on-line purchase. Once the media asset groups are made available for on-line purchase, users can browse, rate and/or purchase the media asset groups at an on-line media store. One example of a media asset group (group of media items) is known as a playlist, which can pertain to a group of audio tracks.